Genelux (GNLX) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
6 Jun, 2026Opening remarks and agenda
Meeting commenced virtually with board members, management, and external advisors present.
Formal business followed the agenda outlined in the notice and proxy statement.
Board and executive committee updates
Election of two Class III directors, James Tyree and Thomas Zindrick, to serve until the 2028 annual meeting.
Shareholder proposals
Two proposals presented: election of directors and ratification of the independent auditor.
No additional proposals were submitted by stockholders in accordance with bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genelux
- Olvi-Vec shows robust efficacy in hard-to-treat cancers, with pivotal data expected this year.GNLX
Fireside chat7 Jun 2026 - Olvi-Vec shows promising late-stage efficacy and immune activation in ovarian and lung cancers.GNLX
Corporate presentation1 Jun 2026 - Net loss narrowed, R&D spending rose, $30M raised, and cash runway extends into Q1 2026.GNLX
Q2 20241 Jun 2026 - Net loss of $20.9M for nine months; cash runway into Q1 2026; key trial data ahead.GNLX
Q3 20241 Jun 2026 - FDA alignment and clinical progress drive R&D, with cash runway into Q1 2026.GNLX
Q4 20241 Jun 2026 - Net loss narrowed to $7.5M in Q1 2025; cash runway to Q3 2026 after equity raises.GNLX
Q1 20251 Jun 2026 - Cash reserves fund operations into Q3 2026 as clinical progress continues amid ongoing losses.GNLX
Q2 20251 Jun 2026 - Net loss reached $22.9M YTD; cash runway extends into Q3 2026, with key data ahead.GNLX
Q3 20251 Jun 2026 - Promising clinical progress and strengthened cash position support continued development into 2027.GNLX
Q4 20251 Jun 2026